RADIOLOGY /// THERAPY RESPONSE EVALUATION

Tempus Pixel provides advanced analysis, tools, and automated reporting from radiology images to help providers accurately track, quantify, and efficiently make RECIST¹ assessments and other clinical decisions.

Segment and measure lesions of interest within radiology images for efficient and consistent therapy response assessments²

Access longitudinal tracking reports that automatically calculates lesion response^3,4

Easily integrate with existing PACS and EHR systems to optimize radiology workflows

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. Doi: https://doi.org/10.1016/j.ejca.2008.10.026
Tempus Pixel Therapy Response Evaluation single-click lesion segmentation feature is semi-automated and powered by DeepLook’s DL Precise (K202084) but is not available for clinical use in the EU. Arterys is the manufacturer of Tempus Pixel, excluding any third party components described in this list. DeepLook is the manufacturer of DL Precise. DL Precise is not CE marked.
In the U.S., Tempus Pixel Lung is FDA-cleared (K203744) but is not indicated for lung nodule detection. Lung nodule automated detection and quantification is powered by InferRead CT (K192880). Arterys Inc is the manufacturer of Tempus Pixel Lung, excluding any third party components described in this list. Infervision is the manufacturer of InferRead CT.
In the EU, Tempus Pixel Lung is CE marked and indicated for lung nodule detection. RECIST is pending CE mark. Arterys Inc is the manufacturer of Tempus Pixel Lung.